Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells

BACKGROUND: Subpopulations of cancer cells with the capacity of generating solid tumors have been characterized. In various cancer types, including prostate cancer cells, a side population (SP) and CD133-expressing cells have been proposed as containing a population cancer cells with stem-like abili...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianjun, Wang, Honghe, Cannon, Virginetta, Wolcott, Karen Marie, Song, Hongbin, Yates, Clayton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180433/
https://www.ncbi.nlm.nih.gov/pubmed/21917149
http://dx.doi.org/10.1186/1476-4598-10-112
_version_ 1782212635635220480
author Zhou, Jianjun
Wang, Honghe
Cannon, Virginetta
Wolcott, Karen Marie
Song, Hongbin
Yates, Clayton
author_facet Zhou, Jianjun
Wang, Honghe
Cannon, Virginetta
Wolcott, Karen Marie
Song, Hongbin
Yates, Clayton
author_sort Zhou, Jianjun
collection PubMed
description BACKGROUND: Subpopulations of cancer cells with the capacity of generating solid tumors have been characterized. In various cancer types, including prostate cancer cells, a side population (SP) and CD133-expressing cells have been proposed as containing a population cancer cells with stem-like ability. Therefore the aim of this work was to determine, in prostate cancer cell lines, the frequency and tumorigenic potential of SP and CD133+ cells. RESULTS: In vitro 2D colony-forming assay and sphere-forming assay, Flow cytometry analysis and magnetic cell sorting were utilized to sort CD133+, CD133- and Side population (SP) cells. Our findings indicate that CD44 and integrin α-6 are uniformly expressed in the hTERT cell lines; however, CD133 is expressed only in a small population (< 0.1%). FACS-sorted CD133+ and CD133- cells exhibited similar tumorigenicity in vitro and in vivo. Additionally, for the hTERT cells, SP rather than CD133 expression showed an 8-fold enhanced tumorigenic potential. The data suggest that SP cells, rather than those with CD133 marker, contain the rare population of CSC capable of producing prostate tumors. CONCLUSION: Collectively, our data suggest that although CD133 is expressed only in a small population of hTERT-immortalized prostate cancer cells, it is not likely to be associated with stem cells, as CD133- and CD133+ cells exhibited similar tumorigenicity. However, SP isolated cells, appear to be enriched with tumorigenic stem-like cells capable of generating palpable tumors.
format Online
Article
Text
id pubmed-3180433
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31804332011-09-27 Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells Zhou, Jianjun Wang, Honghe Cannon, Virginetta Wolcott, Karen Marie Song, Hongbin Yates, Clayton Mol Cancer Research BACKGROUND: Subpopulations of cancer cells with the capacity of generating solid tumors have been characterized. In various cancer types, including prostate cancer cells, a side population (SP) and CD133-expressing cells have been proposed as containing a population cancer cells with stem-like ability. Therefore the aim of this work was to determine, in prostate cancer cell lines, the frequency and tumorigenic potential of SP and CD133+ cells. RESULTS: In vitro 2D colony-forming assay and sphere-forming assay, Flow cytometry analysis and magnetic cell sorting were utilized to sort CD133+, CD133- and Side population (SP) cells. Our findings indicate that CD44 and integrin α-6 are uniformly expressed in the hTERT cell lines; however, CD133 is expressed only in a small population (< 0.1%). FACS-sorted CD133+ and CD133- cells exhibited similar tumorigenicity in vitro and in vivo. Additionally, for the hTERT cells, SP rather than CD133 expression showed an 8-fold enhanced tumorigenic potential. The data suggest that SP cells, rather than those with CD133 marker, contain the rare population of CSC capable of producing prostate tumors. CONCLUSION: Collectively, our data suggest that although CD133 is expressed only in a small population of hTERT-immortalized prostate cancer cells, it is not likely to be associated with stem cells, as CD133- and CD133+ cells exhibited similar tumorigenicity. However, SP isolated cells, appear to be enriched with tumorigenic stem-like cells capable of generating palpable tumors. BioMed Central 2011-09-14 /pmc/articles/PMC3180433/ /pubmed/21917149 http://dx.doi.org/10.1186/1476-4598-10-112 Text en Copyright ©2011 Zhou et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Zhou, Jianjun
Wang, Honghe
Cannon, Virginetta
Wolcott, Karen Marie
Song, Hongbin
Yates, Clayton
Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells
title Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells
title_full Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells
title_fullStr Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells
title_full_unstemmed Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells
title_short Side population rather than CD133(+ )cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells
title_sort side population rather than cd133(+ )cells distinguishes enriched tumorigenicity in htert-immortalized primary prostate cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180433/
https://www.ncbi.nlm.nih.gov/pubmed/21917149
http://dx.doi.org/10.1186/1476-4598-10-112
work_keys_str_mv AT zhoujianjun sidepopulationratherthancd133cellsdistinguishesenrichedtumorigenicityinhtertimmortalizedprimaryprostatecancercells
AT wanghonghe sidepopulationratherthancd133cellsdistinguishesenrichedtumorigenicityinhtertimmortalizedprimaryprostatecancercells
AT cannonvirginetta sidepopulationratherthancd133cellsdistinguishesenrichedtumorigenicityinhtertimmortalizedprimaryprostatecancercells
AT wolcottkarenmarie sidepopulationratherthancd133cellsdistinguishesenrichedtumorigenicityinhtertimmortalizedprimaryprostatecancercells
AT songhongbin sidepopulationratherthancd133cellsdistinguishesenrichedtumorigenicityinhtertimmortalizedprimaryprostatecancercells
AT yatesclayton sidepopulationratherthancd133cellsdistinguishesenrichedtumorigenicityinhtertimmortalizedprimaryprostatecancercells